2019-07-08 11:00 am - 2020-07-08 12:00 pm
|As global biopharma leaders make contingency plans and build scenarios for a COVID-19 world, many are left to wonder: What will 2021 look like?|
In Part 2 of this exclusive webinar series, BioCentury and McKinsey & Co. discuss key findings from a recent BioCentury industry survey about how 2021 will look different for biopharma companies. Frombudgeting, to clinical trials, to deals and financings, to supply chains, COVID-19 has fundamentally changed how the biopharma industry will operate in 2021, and beyond.
Following the initial discussion, BioCentury and McKinsey will convene a panel of biotech C-Suite to discuss the survey findings and what industry should expect in 2021.
|Session Chairs: |
Simone Fishburn, Ph.D. - VP & Editor in Chief/ BioCentury Inc.
Jorge Santos da Silva - Partner/ McKinsey & Co.
Bahija Jallal, Ph.D. - Chief Executive Officer/ Immunocore